

Reducing the Burden of **ATRIAL FIBRILLATION:** A Whiteboard Animated Tour of Antiarrhythmic Drugs for Cardiologists



FACULTY
INFO



This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from Sanofi US.

Reducing the Burden of Atrial Fibrillation: A Whiteboard Animated Tour of Antiarrhythmic Drugs for Cardiologists

FACULTY

Program Chair

Gerald Naccarelli, MD

Professor and Bernard Trabin Chair in Cardiology, Department of Medicine
Chief, Division of Cardiology
Penn State Heart and Vascular Institute
Penn State University College of Medicine
Hershey, PA

Kenneth Ellenbogen, MD

Kimmerling Professor of Medicine
VCU School of Medicine
Richmond, VA

Peter Kowey, MD

Emeritus Chief and WW Smith Chair
Lankenau Heart Institute
Professor of Medicine and Clinical Pharmacology
Jefferson Medical College
Wynnewood, PA

John Osborne, MD, PhD, FACC, FNLA

Director of Cardiology
State of the Heart Cardiology
National Director of Cardiology and Preventive Cardiology
LowT Center/HerKare
Dallas, TX

Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS

Associate Professor of Medicine
Director, Cardiac Electrophysiology
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC

Vivek Reddy, MD

Director of Cardiac Arrhythmia Services
Mount Sinai Hospital
New York, NY

James Reiffel, MD

Professor Emeritus of Medicine
Columbia University
New York, NY

PROGRAM OVERVIEW

This live activity targets healthcare gaps related to the treatment and management of atrial fibrillation (AF), impacting outcomes through guidelines and best practices, appropriate antiarrhythmic use and shared decision-making.

- By addressing these gaps, you can assess whether your approach to AF management through utilization of current treatment guidelines and strategies for shared decision making – could be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying appropriate candidates for antiarrhythmic intervention, utilizing clinical trial and real-world data on efficacy and safety to affect patient outcomes.
- You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to antiarrhythmic mechanisms of action and consequences related to interactions with other cardiovascular agents.

TARGET AUDIENCE

This activity is designed to meet the educational needs US-based cardiologists and other HCPs involved in the care of patients with AF.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

- Discuss current guidelines and best practices to improve outcomes for patients with AF in clinical practice
- Review clinical trial and real-world data on the efficacy and safety of antiarrhythmic drugs used for the management of AF
- Adopt shared decision-making approaches aimed at improving patient outcomes in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 *AMA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with atrial fibrillation.

Credits: 1.0 ANCC Contact Hour

CNE Accreditation Statement: Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Gerald Naccarelli reports that he is a consultant for Acesion Pharma, GlaxoSmithKline, Janssen Pharmaceutica, Milestone Pharmaceuticals, Omeicos Therapeutics and Sanofi

Dr. Kenneth Ellenbogen reports that he is on the Speakers Bureau, serves as a consultant and has completed contracted research for Abbott, Biosense, Boston Scientific, Medtronic and Webster.

Dr. Peter Kowey reports that he has stock in Biotelemetry and is a consultant for Sanofi

Dr. John Osborne has no relationships to disclose

Dr. Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS TBD

Dr. Vivek Reddy, MD TBD

Dr James Reiffel reports that he is on the Speakers Bureau for Sanofi, works as a consultant for Acesion Pharma, Amarin, Correvio and Medtronic, and provides research support to Johnson & Johnson and Janssen

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.

Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the live activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at <http://medlearninggroup.com/privacy-policy/>

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com



This activity is provided by Med Learning Group.



This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from Sanofi US.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

***Reducing the Burden of Atrial Fibrillation:
A Whiteboard Animated Tour of
Antiarrhythmic Drugs for Cardiologists***

Gerald V. Naccarelli, MD

Bernard Trabin Chair of Cardiology
Professor of Medicine; Chief, Division of Cardiology
Associate Clinical Director, Penn State Heart and Vascular Institute
Penn State University College of Medicine
Hershey, PA

Disclosures

- Please see Program Overview for specific speaker disclosure information.
- During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Educational Objectives

- Discuss current guidelines and best practices to improve outcomes for patients with atrial fibrillation (AF) in clinical practice
- Review clinical trial and real-world data on the efficacy and safety of antiarrhythmic drugs used for the management of AF
- Adopt shared decision-making approaches aimed at improving patient outcomes in clinical practice

AF: A Significant Healthcare Issue

AF affects ~ **3-6 million people** in the US; important to differentiate:


- AF is associated with increases in aging and chronic heart disease (especially HF)
- **Median age 75 y**, although 70% are between 65 and 85 y and 84% > 65 y



AF = atrial fibrillation; US = United States; HF = heart failure.


Fuster V, et al. *Circulation*. 2006;114:700-752. Thom T, et al. *Circulation*. 2006;113:e85-e151. Feinberg W, et al. *Arch Intern Med*. 1995;155:469-473. Wikstrom J, et al. *Am J Cardiol*. 1998;81:3C-15C. Benjamin E, et al. *Circulation*. 1998;98:946-952. Wang T, et al. *Circulation*. 2003;107:2920-2925. Miyasaka Y, et al. *Circulation*. 2006;114:119-125. Chugh S, et al. *J Am Coll Cardiol*. 2001;37:371-378. CDC. What is atrial fibrillation? 2020 (https://www.cdc.gov/heartdisease/atrial_fibrillation.htm). Accessed October 19, 2020. ACC. Impact and consequences of atrial fibrillation. 2018 (<https://www.acc.org/latest-in-cardiology/articles/2018/08/06/12/42/cover-story-impact-and-consequences-of-atrial-fibrillation>). Accessed October 19, 2020.

AF: Clinical Presentation



Hindricks G, et al. 2020 European Society of Cardiology (ESC) Guidelines. *Eur Heart J*. 2020;00:1-125.


Risk Factors for AF



COPD = Chronic Obstructive Pulmonary Disorder.

Hindricks G, et al. 2020 ESC Guidelines. *Eur Heart J*. 2020;00:1-125.

Maintaining Normal Sinus Rhythm (NSR) May Slow Down AF Disease Progression



Wyse G, Gersh BJ. *Circulation*. 2004;109:3089-3095.

AF Related Outcomes

	AF Related Outcome	Frequency in AF	Mechanism(s)
	Death	1.5- to 3.5-fold increase	Excess mortality related to: • HF, comorbidities • Stroke
	Stroke	20-30% of all ischemic strokes, 10% of cryptogenic strokes	• Cardioembolic or • Related to comorbid vascular atheroma
	LV dysfunction/ heart failure	In 20-30% of patients with AF	• Excessive ventricular rate • Irregular ventricular contractions • A primary underlying cause of AF
	Cognitive decline/ vascular dementia	Hazard ratio 1.4/1.6 (irrespective of stroke history)	• Brain white matter lesions, inflammation • Hypoperfusion • Microembolism
	Depression	Depression in 16-20% (even suicidal ideation)	• Severe symptoms and decreased QoL • Drug side effects
	Impaired quality of life	>60% of patients	• Related to AF burden, comorbidities, psychological functioning, and medication • Distressed personality type
	Hospitalizations	10-40% annual hospitalization rate	• AF management, related to HF, MI, or AF related symptoms • Treatment-associated complications

LV = left ventricular; QoL = quality of life; MI = myocardial infarction.
Hindricks G, et al. 2020 ESC Guidelines. *Eur Heart J*. 2020;00:1-125.

AF Clinical Evaluation: Etiologic Assessment

Treatment of AF
dependent on

• Etiologic factors
cause, severity, reversible/modifiable


• Patient factors
embolic risk, concomitant disorders

- An *etiologic* assessment is **appropriate for all patients with AF**; at a *minimum*, this evaluation requires:
 - History (including family history and CHA₂DS₂-VASc)
 - Physical examination
 - Serum chemistries, complete blood count (CBC), TSH
 - Electrocardiogram (ECG)
 - Echocardiogram
 - Stress testing (if CAD is reasonably suspect from the above)
 - Chest x-ray (if pulmonary disease is suspect and/or HF is a consideration)

TSH = thyroid-stimulating hormone; CAD = coronary artery disease.

American College of Cardiology (ACC). 2014 ACC Guidelines. (<http://eguideline.guidelinecentral.com/i/387793-atrial-fibrillation/07m4=>). Accessed October 5, 2020.


Treatment Options for AF



CCBs = Calcium channel blockers; SR = sinus rhythm; LA = left atrial.

American College of Cardiology (ACC). 2014 ACC Guidelines. (<http://eguideline.guidelinecentral.com/i/387793-atrial-fibrillation/07m4=>). Accessed October 5, 2020. January C, et al. *JACC*. 2019;74:104-132.

AHA/ACC/HRS: AF Rate Control



Trials of Rhythm and Rate Control in AF AFFIRM, RACE, AF-CHF, PIAF, STAF, HOT CAFE

Major overall findings

- Rhythm control was **NOT** superior to rate control in terms of morbidity/mortality
- Rate control is an acceptable primary therapeutic option
- Patients with AF and risk factors for stroke should receive anticoagulation indefinitely, even when SR appears to be restored and maintained

Both strategies are acceptable *but...*

Rate control does not apply to all patients with AF

- Particularly those symptomatic despite rate control
- Patients in whom exercise tolerance is important
- Patients in whom rate control failed
- Some patients with depressed LV function

Clinicians should adapt the therapeutic strategy to the individual

AFFIRM = AF Follow-up Investigation of Rhythm Management; RACE = Rate Control vs Electrical cardioversion for persistent AF; AF-CHF = AF and Congestive Heart Failure trial; PIAF = Pharmacological Intervention in AF; STAF = Strategies of Treatment of AF; HOT CAFE = How to Treat Chronic AF Polish trial.
 Hohnloser S, et al. *Lancet*. 2000;356:1789-1794. Wyse D, et al. *N Engl J Med*. 2002;347(23):1825-1833. Van Gelder I, et al. *N Engl J Med*. 2002;347(23):1834-1840. Opolski G, et al. *Chest*. 2004;126:476-486. Vora A, et al. *J Cardiovasc Pharmacol Ther*. 2004;9(2):65-73. Ogawa S, et al. *Circ J*. 2009;73(2):242-248. Carlsson J, et al. *J Am Coll Cardiol*. 2003;41(10):1690-1696. Roy D, et al. *N Engl J Med*. 2008;358(25):2667-2677. Reiffel J, *J Atr Fibrillation*. 2008;1:40-52.

Rate vs Rhythm Control Studies: Other Findings

Study	Findings
J-RHYTHM*	Rhythm control improved primary endpoint ($P = .0128$)
SAFE-T	- Maximal exercise duration better in SR group at 8 wks ($P = .01$) and 1 y ($P = .02$) - QoL more likely to improve in symptomatic patients
STAF	Remaining in AF had higher risk for embolic events (pNS Rate vs Rhythm)
PIAF	Exercise tolerance better in NSR group
Gillinov A, et al	No difference in outcomes after cardiac surgery
ORBIT-AF	- No difference in outcomes - Rhythm control was associated with more CV hospitalizations hazard ratio = 1.24 (1.10-1.39), $P = .0003$
RACE	In sinus rhythm, LV function significantly improved ($P < .05$)

*J-RHYTHM (Japanese Rhythm Management Trial for AF) studied composite of total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure, or physical/psychological disability requiring alteration of treatment strategy.

SAFE-T = Sotalol Amiodarone Atrial Fibrillation Efficacy Trial; ORBIT-AF = Outcomes Registry for Better Informed Treatment of AF; pNS = P non-significant. Ogawa S, et al. *Circ J*. 2009;73:242-248. Singh S, et al. *J Am Coll Cardiol*. 2006;48:721-730. Hagens V, et al. *Heart Rhythm*. 2005;2:19-24. Carlsson J, et al. *J Am Coll Cardiol*. 2003;41:1690-1696. Gillinov A, et al. *N Engl J Med*. 2016;374:1911-1921. Noheria A, et al. *J Am Coll Card: Clin Electrophysiol*. 2016;2:221-229. Hohnloser S, et al. *Lancet*. 2000;356:1789-1794.

Case Study 1

- A 68-y-old male has a 1-y history of paroxysmal AF lasting from 2-6 hours
- He has symptomatic palpitations and is managed with metoprolol succinate 100 mg once daily
- His ventricular rate during paroxysmal atrial fibrillation (PAF) on metoprolol is 80 beats per minute (bpm)
- He has a history of hypertension and NSTEMI 3 y ago requiring placement of a drug-eluting stent to his left anterior descending artery
- Past history is negative for diabetes, stroke, or CHF
- Other medications: atorvastatin 40 mg a day, losartan 50 mg a day, and aspirin 81 mg a day

NSTEMI = non-ST segment elevation myocardial infarction ; CHF = congestive heart failure.

Case Study 1: Question 1

- Labs: TSH – normal; creatinine clearance (CrCl) – 76 ml/min
- ECG: Sinus rhythm with rate of 78 bpm; normal with QT interval corrected for heart rate (QTc) of 422 msec
- Echocardiogram: left ventricular ejection fraction (LVEF) – 60%; LV wall thickness 1.2 cm; LA diameter – 4.3 cm
- Stress nuclear study in last year: normal LVEF (60%) with no evidence of ischemia

What is the optimal heart rate control goal for this patient?


- a) Resting heart rate < 90 bpm
- b) Resting heart rate < 100 bpm
- c) Resting heart rate < 120 bpm

AF: Heart Rate Goal

- Resting (apical) heart rate ≤ 80 bpm
- In RACE II [hazard ratio: 0.84 (0.58-1.21)]:
 - Strict rate control was 76 ± 14 bpm
 - Lenient rate control was 85 ± 14 bpm
- Ambulatory (Holter) heart rate ≤ 90 bpm
- Stress test: peak heart rate 20% < age-predicted maximum
- Rate to reverse tachycardia-induced cardiomyopathy not known

Wyse DG, et al. *N Engl J Med.* 2002;347(23):1825-1833. Van Gelder I, et al. *N Engl J Med.* 2010;362:1363-1373.

RACE-II: Strict vs Lenient Heart Rate (HR) Control in Patients With Permanent AF



Primary outcome: composite of CV death, hospitalization for HF, stroke, systemic embolism, bleeding, and life-threatening arrhythmic events

Strict control: target resting HR < 80 bpm; target exercise HR < 110 bpm

Lenient control: target resting HR < 110 bpm

Van Gelder I, et al. *N Engl J Med.* 2010;362:1363-1373.

Strict vs Lenient Rate Control of AF and HF

On day of discharge:
13,981 patients with
AF and HF

- 9,100 (65.0%) had **strict** rate control
- 4,617 (33.0%) had **lenient** rate control
- 264 (1.9%) had **poor** rate control by resting HR

Lenient rate control	Adjusted risk of death	All-cause readmission	Death or all-cause readmission	Cardiovascular readmission
At 90 days (after multivariable adjustment, compared with strict rate control)	Higher HR = 1.21, 95% CI (1.11-1.33) P < .001	Higher HR = 1.09, 95% CI (1.03-1.15) P = .002	Higher HR = 1.11, 95% CI (1.05-1.18) P < .001	Not Higher HR = 1.08, 95% CI (1.00-1.16) P = .051

The presence or absence of reduced ejection fraction *did not* impact the magnitude of most observed associations


Conclusions
(in patients with HF and AF)

- **2 of 3** patients had a heart rate that met **strict** rate control goals at discharge
- Heart rates > 80 beats/min were associated with adverse outcomes *irrespective* of LVEF

Hess P, et al. *Am J Cardiol.* 2020;125:894-900.

EAST-AFNET: Primary Safety Outcome

The primary safety outcome was a composite of death, stroke, or serious adverse events related to rhythm-control therapy



Sinus rhythm at 2 years: **82.1% in early rhythm control** vs 60.5% in usual care study arm

Kirchoff P, et al. *N Engl J Med.* 2020;383:1305-1316.

EAST-AFNET 4

	Patients With Event in Early Rhythm Control (n=1395)	Patients With Event in Usual Care (n=1394)	Uncorrected Hazard Ratio [95% CI]
Cardiovascular death	67 / 6915 (1.0)	94 / 6988 (1.3)	0.72 [0.52-0.98]
Stroke	40 / 6813 (0.6)	62 / 6856 (0.9)	0.65 [0.44-0.97]
Hospitalization with worsening of heart failure	139 / 6620 (2.1)	169 / 6558 (2.6)	0.81 [0.65-1.02]
Hospitalization with acute coronary syndrome	53 / 6762 (0.8)	65 / 6816 (1.0)	0.83 [0.58-1.19]

The primary safety outcome was a composite of death, stroke, or serious adverse events related to rhythm-control therapy.

Kirchoff P, et al. *N Engl J Med.* 2020;383:1305-1316.

EAST-AFNET 4 and AFFIRM: Differences

	AFFIRM	EAST-AFNET
Early initiation of rhythm control		X
Study centers	North America	Europe
More persistent AF	X	
Higher % hypertension, valvular heart disease		X
Dronedaron and catheter ablation use		X
High digoxin use	X	
High sotalol and amiodarone use	X	
Non-vitamin K antagonist oral anticoagulants (NOAC) use		X
Oral anticoagulant (OAC) use equivalent in 2 arms/ lower stroke rate		X
All-cause mortality primary endpoint	X	
Composite endpoint: CV death, stroke, worsening HF, acute coronary syndromes (ACS)		X
Rhythm control: Higher hospitalizations	X	
Safety outcomes no different in 2 arms of study		X
High # lost to follow-up		X

The AFFIRM Investigators. *N Engl J Med.* 2002;347:1825-1833. Kirchoff P, et al. *N Engl J Med.* 2020;383:1305-1316.

21


Case Study 1: Question 2

- After 6 months, he represents with complaints of palpitations that began 1 week ago; he is still taking metoprolol succinate 100 mg daily with no missed doses as well as apixaban for 6 months.
- EKG: AF with rate of 85 bpm; QTc of 410 msec
- Echocardiogram: LVEF – 45%

What would you change in his management?

- Continue present treatment
- Add dronedarone and reassess in 1 week
- Increase metoprolol dose to 200mg/day

AHA/ACC/HRS: AF Rhythm Control



AAD Classification and Pharmacokinetics

Antiarrhythmic Class		Agent	CYP Substrate	P-gp	Enzymes/Transporters Inhibited
Class I	Class Ia	Quinidine	3A4	Yes	3A4, 2D6, P-gp
		Procainamide	No	No	None known
		Disopyramide	3A4	No	None known
	Class Ib	Lidocaine	1A2, 2B6, 2D6	No	1A2
		Mexiletine	2D6, 1A2	No	1A2
	Class Ic	Flecainide	2D6	No	2D6
		Propafenone	1A2, 2D6, 3A4	No	2D6
Class II	Propranolol	2D6, 1A2, 2C19	Yes	P-gp, weakly 2D6	
	Bisoprolol	3A4 (minor: 2D6)	Possibly	None known	
	Metoprolol	2D6	No	None known	
	Carvedilol	2D6, 2C9 (minor: 3A4, 1A1, 1A2, 2C19, 2E1)	No	P-gp	
Class III	Amiodarone	3A4, 2C8	No	1A2, 2D6, 2C9, 3A4, P-gp	
	Dronedarone	3A4	No	3A4, 2d6, P-gp	
	Sotalol	No	No	None known	
	Ibutilide	No	No	None known	
	Dofetilide	Insignificant	No	None known	
Class IV	Verapamil	3A4, 3A5, 2C8 (minor: 1A2, 2C9, 2D6, 2E1)	Yes	3A4, P-gp	
	Diltiazem	3A4, 2C8, 2C9, 2C19	Yes	3a4, possibly 2D6, P-gp	

CYP = cytochrome P-450; P-gp = P-glycoprotein.

Konieczny K, Dorian P. *JICRM*. 2019;10(3):3552-3559.

Whiteboard Presentation

Please scan the QR code below for a brief animation exploring the mechanisms of action of antiarrhythmics indicated for rhythm control in AF



Antiarrhythmic Therapy With AADs

What is the goal?


AF is usually recurrent and rarely lethal →
Keep goals realistic

- Reduce the frequency, duration, and severity of events
- Minimize the risks of treatment (drug, ablation, etc)

- **AAD therapy** (per the AHA/ACC/HRS and ESC algorithmic guidelines) *must be selected based on:*
 - **Anticipated efficacy** (most have ~40-60% efficacy; amiodarone is a bit higher)
 - **Tolerance** (highest: dofetilide, dronedarone, flecainide, propafenone, sotalol)
 - **Proarrhythmic risk** (IC in SHD, TDP with QT prolonging AADs)
 - **Organ toxicity** (highest with amiodarone, PA, quinidine)
 - **Effects on SN and conduction system** (least with dofetilide)
 - **LV dysfunction** (safest with dofetilide and amiodarone)

AADs = antiarrhythmic drugs; SHD = structural heart disease; TDP = torsades de pointes; PA = procainamide; SN = sinus node.
Camm A, et al. *Eur Heart J*. 2010;31:2369-2429. Fuster V, et al. *J Am Coll Cardiol*. 2006;48:e149-e246. Naccarelli GV, et al. *Bus Brief: US Cardiol*. 2004;1-5.

Efficacy of AADs in AF Trials



*At 6 months; †Mean follow-up 7 months.

CTAF = Canadian Trial of Atrial Fibrillation; SAFE-T = Sotalol Amiodarone Atrial Fibrillation Efficacy Trial; DAFNE = Dronedaron Atrial Fibrillation Study after Electrical Cardioversion; EURIDIS = European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedaron for the Maintenance of Sinus Rhythm; ADONIS = American-Australian-African Trial with Dronedaron in Atrial Fibrillation or Flutter for the Maintenance of Sinus Rhythm; DIONYSOS = Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Dronedaron vs Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF.
 Naccarelli G, et al. *Clin Med Insights Cardiol.* 2011;5:103-119. Roy D, et al. *Am J Cardiol.* 1997;80:464-468. Singh B, et al. *N Engl J Med.* 2005;352(18):1861-1872. AFFIRM Investigators. *J Am Coll Cardiol.* 2003;42:20-29. Touboul P, et al. *Eur Heart J.* 2003;24:1481-1487. Singh B, et al. *N Engl J Med.* 2007;357(10):987-999. Le Heuzey J, et al. *J Cardiovasc Electrophysiol.* 2010;21:597-605.

Propafenone vs Flecainide

	Propafenone	Flecainide
Metabolism	Hepatic (P450D6)	Hepatic – 70% Renal – 30%
Active metabolites	5-OH Propafenone	None
β-blocking activity	Yes	No
Drug interactions	Digoxin Warfarin	Amiodarone
Onset/offset kinetics	Fast/slow	Slow/slow
K-channel blocker	No	Low
Saturated pharmacokinetics	Yes	No

Lei M, et al. *Circulation.* 2018;138:1879-1896. Flecainide (Tambacor® PI). 2015 (<https://davisplus.fadavis.com/3976/meddeck/pdf/flecainide.pdf>). Accessed October 19, 2020.

Amiodarone: Adverse Effects

- Well tolerated hemodynamically with **minimal negative inotropic effects**
- Drug interactions: digoxin, warfarin, quinidine, procainamide, and flecainide

System	Adverse Effect
Cardiac	• Bradycardia (may require backup permanent pacing) but <i>low-dose amiodarone may minimize</i> • Prolongs action potential duration (APD); however, torsade de pointes (TdP) and development of incessant sustained ventricular tachycardia (VT) is <i>rare</i> • Raises defibrillation threshold (DFT)
Dermatologic	Skin photosensitivity Bluish-gray discoloration
Endocrine	Hypothyroidism – requires addition of thyroid replacement Hyperthyroidism – may require therapy discontinuation
Hepatic	Asymptomatic, transient ↑ of hepatic enzymes and drug-induced hepatitis (2%)
Neurologic	Peripheral neuropathy and myopathy Usually resolves with ↓ dose
Ocular	Corneal microdeposits
Pulmonary	Interstitial pneumonitis
Vascular	Venous sclerosis can be minimized if intravenous (IV) amiodarone is given via central venous line

Naccarelli G, et al. *Pharmacotherapy*. 1985;5:298-313.

Dofetilide vs Amiodarone

- Greater efficacy for termination of AF
- Similar safety in CHF and post-MI patients
- Little sinus, atrioventricular nodal (AVN), or His Purkinje System (HPS) effect
- No end-organ toxicity or added cost following thyroid, liver, lung, and eye complications
- Dofetilide **requires in-hospital initiation** due to TdP risk; rate control drug
 - TdP is of lower concern based on in-hospital telemetry, proper patient screening, dosing by creatinine clearance
- Renal clearance minimizes use in patients with chronic renal failure (CRF)
- Both have multiple pharmacokinetic drug interactions
- QT interval is a poor man's blood level

Wolbrette D, et al. *J Cardiovasc Pharm Ther*. 2019;24:3-10.

Ibutilide vs Amiodarone

- Meta-analysis (8 studies, 506 patients) of IV ibutilide and amiodarone in AF and atrial flutter (AFL)
- Enhanced **total efficacy** in cardioversion of AF and AFL; however, *no significant difference in cardioversion rate for AF*
- Cardioversion time of AF and AFL shorter than amiodarone
- No significance in total adverse reactions; however, cardiovascular adverse reaction rate of ibutilide group is significantly higher than amiodarone

Xiao D, Wenhui D. *Heart*. 2011;97:A122.

Sotalol vs Amiodarone

- Sotalol can significantly delay time to AF recurrence
- Both are equally efficacious in symptomatic and asymptomatic patients
- Both are equally efficacious in converting AF to sinus rhythm
 - Amiodarone is superior for maintaining sinus rhythm
 - **Both with similar efficacy in ischemic heart disease**
- Side effect profiles similar in follow-up (SAFE-T)
- Was associated with ↑ risk all-cause mortality when compared with no AAD (hazard ratio – 1.53, 95% CI), but **↓ risk of death when compared with amiodarone** (hazard ratio – 0.72, 95% CI)

Piccini J, et al. *Am J Cardiol*. 2014;114:716-722. Singh B, et al. *N Engl J Med*. 2005;352:1861-1872.

Clinical Profiles for Amiodarone and Dronedarone

	Amiodarone	Dronedarone
Iodine moiety	Yes	No
T _{1/2}	53 days	14-30 hours
Blocks I _{Kr} ; I _{Ks} ; B ₁ ; I _{Ca} ; I _{to} ; I _{Na}	Yes	Yes
Dosing	Daily after loading	BID with meals
Food effect	Yes	Yes
CYP4503A4 metabolism	Yes	Yes
Inhibits tubular secretion of creatinine	Yes	Yes
Increase QT but low TdP	Yes	Yes
Efficacy in suppressing AF	65%	50%
Efficacy in suppressing ventricular tachyarrhythmia	Yes	Not well studied
Decreases CV hospitalization	No	Yes
Warfarin interaction	Yes	No
Pulmonary/thyroid toxicity	Yes	No
Safety concerns in CHF	SCD-HEFT NYHA III	ANDROMEDA


Wolbrette D, et al. *Vasc Health Risk Manage.* 2010;(6):517-523.

Dronedarone: ATHENA and PALLAS

ATHENA: PAF or Persistent AF

Primary outcome: time to first CV hospitalization or death

N = 4628 (PAF or persistent AF) randomized
≥75 y with or w/o additional RF or ≥70 y and ≥1 RF
(HTN, DM, prior stroke/TIA, LA diameter ≥50 mm, LVEF ≤0.40)




Patients at risk

Placebo	2327	1858	1625	1072	385	3
Dronedarone	2301	1963	1776	1177	403	2

PALLAS: Permanent AF

N = 3236; ≥ 65 y with > 6 mo h/o permanent AF and risk factors for major vascular event

Study stopped for safety reasons



RF = risk factor; HTN = hypertension; DM = diabetes mellitus; TIA = transient ischemic attack; h/o = history of.
Hohnloser S, et al. *N Engl J Med.* 2009;360:668-678. Connolly S, et al. *N Engl J Med.* 2011;365:2268-2676. Singh D, et al. *J Am Coll Cardiol.* 2010;55:1569-1576.

Dronedarone: Real-World Studies

Meta-analyses and recent real-world (RW) studies conducted on dronedarone

Meta-analysis	Studies Analyzed/Registries	Main Conclusion (dronedarone)
Piccini J, et al	9 RCTs (4 dronedarone, 4 amiodarone, 1 RCT for direct comparison analysis)	Fewer AEs than amiodarone; less effective at SR maintenance
Freemantle N, et al	39 RCTs (amiodarone, dronedarone, flecainide, propafenone, sotalol)	Associated w/ <i>lowest rate of proarrhythmia</i> of AADs
Dagres N, et al	7 RCTs (dronedarone)	↓ risk of CVA or TIA in PAF or persistent AF
Chatterjee S, et al	7 RCTs (dronedarone)	↑ all-cause mortality in wide population spectrum
Hohnloser S, et al	7 RCTs (dronedarone)	Permanent AF <i>most important predictor</i> of CV death w/use
Lafuente-Lafuente C, et al	59 RCTs (quinidine, disopyramide, aprindine, bidisomide, flecainide, propafenone, metoprolol, amiodarone, azimilide, dofetilide, dronedarone, sotalol)	Several class IA, IC, II, and III drugs have moderate effect on maintaining SR following conversion of AF
Diemberger I, et al	12 RCTs and 7 OBS (dronedarone)	Recurrent AF prophylaxis not associated w/↑ risk of death
Recent RW Studies	Registries Used	
Friberg L	Swedish patient register	Treatment for AF did not have ↑ risk of death or liver disease
Friberg L	Swedish patient register	Major bleeding rare in AF treatment w/apixaban + dronedarone
Friberg L	Swedish patient register	↓ risk pro-arrhythmic death vs sotalol
Grimaldi-Bensouda L, et al	PGRx surveillance system	Associated w/ <i>class III AAD use</i> & onset of acute liver injury
Ehrlrich J, et al	German IQVIA database	↓ risk of MI & CVA vs other AADs; no toxic liver disease reported
Mochalina N, et al	Swedish national quality registry (Auricula)	↓ dose of dabigatran + dronedarone did not ↑ plasma dabigatran concentration

AEs= adverse events; OBS = observational study; ACT = randomized controlled trial.
Boriani G, et al. *Europace*. 2019;21:1764-1775.

US Department of Defense (DOD) Real-World Outcomes: Dronedarone vs Other Antiarrhythmic Drugs

Outcomes	Dronedarone (N=6349)		Other AAD (N=12,698)		Hazard Ratio (Dronedarone/Other)
	N (%)	Event	N (%)	Event	Hazard Ratio (95% CI)
Cardiovascular hospitalization	586 (9.23%)	149.48	1315 (10.36%)	173.57	0.87 (0.79, 0.96) P = .006
Cardiovascular hospitalization/death from any cause	598 (9.42)	151.32	1364 (10.74%)	178.60	0.86 (0.78, 0.95) P = .002

Goehring EL, et al. *Am J Cardiol*. 2020;00:1-7.

Other AAD Real-World Data

- ORBIT-AF and AF: Focus on Effective Clinical Treatment Strategies (AFFECTS) registry demonstrated amiodarone was often used even when more front-line guideline-recommended drugs were available
- The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study demonstrated that class IC AADs (flecainide or propafenone) as initial treatment for AF were associated with lower risk of hospitalization and cardiovascular events than class III drugs (sotalol or dofetilide)

Reiffel J, et al. *Am J Cardiol*. 2010;105:1122-1129. Pokorney S, et al. *Am Heart J*. 2020;220:145-154. Kipp R, et al. *J Am Coll Cardiol : Clin Electrophysiol*. 2019;5:231-241.

Considerations in Choosing an Antiarrhythmic Drug

- Efficacy
- Safety (end-organ toxicity, mortality, proarrhythmic risk)
- Morbidity (bradyarrhythmias, negative inotropy, subjective toxicity)
- Quality of life
- Dosing convenience (patient compliance)
- Outpatient initiation
- Interactions (drug-drug, drug-device)
- Metabolism
- Cost (drug, follow-up)

Naccarelli G, et al. *Bus Briefing: US Cardiol*. 2004;1-5. Zimetbaum P. *Circulation*. 2012;125:381-389.

All Antiarrhythmics Are Not Alike

- Binding characteristics
 - Onset-offset kinetics
 - Open or inactivated state blockade
- Additional channel or autonomic blocking properties
- Proarrhythmic incidence
- Inotropic actions
- Organ toxicity and nuisance symptoms
- Drug interactions
- Metabolism
 - Active metabolites with a different mechanism of action

Lei M, et al. *Circulation*, 2018;138:1879-1896.

Whiteboard Presentation

Please scan the QR code below for a brief animation investigating the pathophysiologic consequences of interactions between selected antiarrhythmics and other cardiovascular agents



Significant AADs and Their CV Drug Interactions

Amiodarone	Dronedarone	Quinidine	Verapamil
↑ International Normalized Ratio (INR) (warfarin) ↑ digoxin level ↑ therapeutic levels: • quinidine • procainamide • flecainide Theoretic increase in DOAC levels Increase in simvastatin levels	↑ digoxin level Theoretic increase in DOAC levels Increase simvastatin levels	↑ digoxin level	Can ↑ therapeutic levels of dofetilide

DOAC = direct oral anticoagulant.

Package inserts for amiodarone, dronedarone, quinidine, and verapamil. Konieczny K, Dorian P. *J Innov Cardiac Rhythm Manage.* 2019;10(3):3552-3559. Wiggins B, et al. *Circulation.* 2016;e468-e495. Frommeyer G, et al. *Int J Cardiol.* 2017;22:74-79.

Outpatient vs Inpatient Initiation of Antiarrhythmics for AF

	In AF		In NSR	
	Hospital	Outpatient	Hospital	Outpatient
Class IA*	X		X	
Class IC*		X [†]		X [†]
Sotalol	X		X	X [‡]
Dofetilide	X		X	
Dronedarone		X		X
Amiodarone		X		X

*After rate control; †No SHD or sinus node/conduction abnormalities; ‡No risk factors for TdP (QT <450 ms, normal electrolytes). SHD = structural heart disease; TdP = Torsade de pointes.

Fuster V, et al. *Circulation.* 2006;114:e257-e354.

AADs: Follow-Up Protocols

Proarrhythmias

- May occur *late*
 - Risk factors develop
 - Drug clearance impaired
- Organ toxicity is ongoing risk with amiodarone
- Permanent AF – discontinue membrane active AADs

Class IC Flecainide, Propafenone

- Coronary artery disease, ventricular disorders
 - ECG, exercise test

Class III Dofetilide, Sotalol


Dronedarone

Amiodarone

- QT interval
- Renal function/chemistry profiles
- ECG if long-lasting and persistent AF suspected
- LFTs and TSH every 6 months, chest x-rays annually, PFTs (if pulmonary toxicity suspected)

Dan G, et al. *Europace*. 2018;20:731-732. January C, et al. *J Am Coll Cardiol*. 2014;64:e1-e76.

Efficacy of Catheter Ablation in Patients With AF



Calkins H, et al. *Circ Arrhythmia Electrophysiol*. 2009;2(4):349-361.

CASTLE-AF:

Catheter Ablation vs Conventional Drug Therapy for AF in HF

397 patients w/LVEF < 35%
and ICD randomized to
CA vs drug therapy
Modified ITT approach

Symptomatic PAF (30%)
Persistent AF (35%)

- Primary endpoint: TM + HF hospitalization **reduced by CA** (28.5% vs 44.6%, RRR 38%, $P = .007$) with mean follow-up of 37 mo
- Secondary endpoints: TM (13.4% vs 25%, RRR 47%), HF hospitalization (20.7% vs 35.9%, RRR 44%), CV mortality (RRR 51%) and CV hospitalization (RRR 28%)
- *LVEF increased more with ablation (8%) than drugs (0.2%, $P = .005$)*
- *AF reduced with ablation at 3 mo; gradually increased over 60 mo of follow-up*

ICD = implantable cardioverter-defibrillator; CA = catheter ablation; TM = total mortality; RRR = relative risk reduction.
Marrouche N, et al. *NEJM*. 2018;378:417-427. European Society of Cardiology, EHRA 2018 Congress News. (<https://www.escardio.org>). Accessed October 21, 2020. Stiles S. Mortality falls after AF ablation in heart failure: CASTLE-AF in print. 2018 (<https://www.medscape.com/viewarticle/892189>). Accessed October 21, 2020.


Catheter Ablation in HF

Recommendation for Catheter Ablation in HF		
COR	LOE	Recommendation
IIB	B-R	AF catheter ablation may be reasonable in selected patients with symptomatic AF and HF w/reduced LVEF (HFrEF) to potentially lower mortality rate and reduce hospitalization for HF NEW: New evidence, including data on improved mortality rate, has been published for AF catheter ablation compared with medical therapy in patients with HF


January C, et al. 2019 AHA/ACC/HRS Guidelines. *Circulation*, 2019;74(1):104-132.

CABANA: Catheter Ablation vs Drug Therapy (ITT)


Primary endpoint
(death, disabling stroke,
serious bleeding,
cardiac arrest)



**All-cause
mortality**




**Mortality or
CV hospitalization**



CABANA = The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial.
Packer D, et al. *JAMA*. 2019;321(13):1261-1274.

CABANA: Recurrent AF ITT After Blanking Period



Packer D, et al. *JAMA*. 2019;321(13):1261-1274.

CABANA Trial: Conclusion

- Ablation compared to drug therapy (ITT):
 - **Did not** produce a significant reduction in the primary endpoint and all-cause mortality
 - **Ablation significantly reduced mortality or cardiovascular hospitalization by 17%**
 - There was a **48% reduction in recurrent AF** with ablation
- Ablation compared to drug therapy (treatment received)
 - 14% reduction in primary endpoint and 17% reduction in mortality or CV hospitalization

Ablation is an **acceptable treatment strategy** for the treatment of AF with **low adverse event rates**

Packer D, et al. *JAMA*. 2019;321(13):1261-1274.

Case Study 2

- A 58-y-old man presents to you after moving to the area
- He complains of dyspnea on exertion and fatigue
- He has a 5-y history of paroxysmal AF with a rate on Holter monitor ranging from 70-120 bpm (average 98 bpm)
- He had a failed catheter ablation procedure for his AF 1 y ago and was treated with sotalol prior to his ablation without control of his AF recurrences
- Additional medical history includes 10-y history of treated hypertension with 1 hospital admission 2 y ago for HFpEF; his history is negative for diabetes, coronary artery disease, and stroke

Case Study 2: Question 1

- Current medications include diltiazem controlled delivery (CD) 120 mg a day and rivaroxaban 20 mg a day with the evening meal
- EKG: AF rate of 120 bpm; QTc 430 msec; no other abnormalities
- Stress nuclear study 1 y ago: normal perfusion, no ischemia or infarction with LVEF 60%
- Echocardiogram: LVEF 55% (diffuse mild hypokinesis); mildly dilated LA (4.8 cm)

In addition to increasing his diltiazem dosage for better rate control during AF episodes, what recommendations do you have for this patient?

- Add an AAD that could be safely initiated as an outpatient such as flecainide, propafenone, or dronedarone
- Reattempt catheter ablation
- Add amiodarone

Atrial Fibrillation and Stroke

Stroke is the most common complication of AF

Incidence of all-cause CVA in AF ¹	Number of CVAs caused by AF	Ischemic CVAs in NVAf	Ischemic CVA risk (elderly > 75 y, uncoagulated AF)	Annualized CVA rates for PAF & persistent AF
5%	1 in 7	90%	5.49 ↑ risk vs < 65 y old	PAF = 3.2% Persistent AF = 3.3%

- Ischemic stroke associated with AF is often *more severe* than stroke from other etiology
- Stroke risk persists even in asymptomatic AF
- In patients with AF <70 y old: 187% greater risk of dementia and 130% increased risk for Alzheimer's

Fuster V, et al. *J Am Coll Cardiol*. 2001;38:1231-1265. Benjamin E, et al. *Circulation*. 1998;98:946-952. Friberg L, et al. *Eur Heart J*. 2012;33:1500-1510. Dulli D, et al. *Neuroepidemiology*. 2003;22:118-123. Page R, et al. *Circulation*. 2003;107:1141-1145. Bunch TJ, et al. *Heart Rhythm*. 2010;7:433-437. Bunch TJ, et al. Heart Rhythm Society. 2009, Boston, MA. BBC News. Heart disorder Alzheimer's link. 2009 (<http://news.bbc.co.uk/2/hi/health/8051800.stm>). Accessed October 21, 2020. CDC. What is atrial fibrillation? 2020 (https://www.cdc.gov/heartdisease/atrial_fibrillation.htm). Accessed October 21, 2020.

Assessing and Balancing Stroke Risk

CHA₂DS₂-VASc Score

Risk Factor	Score
Congestive heart failure/ LV dysfunction	1
Hypertension	1
Age ≥ 75 y	2
Diabetes	1
Stroke/TIA/TE history	2
Vascular disease	1
Age 65-74 y	1
Sex category, female	1
MAXIMUM	9

Adjusted Risk

Total Score	CHA ₂ DS ₂ -VASc (%/y)
0	0
1	1.3
2	2.2
3	3.2
4	4.0
5	6.7
6	9.8
7	9.6
8	6.7
9	15.2



LV = left ventricle; TE = thromboembolism; TIA = transient ischemic attack.

1. Lip G, et al. *Chest*. 2010;137:263-272. European Society of Cardiology. *Europace*. 2010;12:1360-1420.

Anticoagulant, Antiplatelet, or Neither: Current Guidelines

Risk Factor	Recommended Therapy	
	ESC	AHA/ACC/HRS
No risk factors CHA ₂ DS ₂ -VASc = 0 in men CHA ₂ DS ₂ -VASc = 1 in women	Prefer neither, or OAC vs antiplatelet (consider bleeding complications and patient preferences)	Neither
CHA ₂ DS ₂ -VASc = 1 in men CHA ₂ DS ₂ -VASc = 2 in women	Prefer OAC, or ASA 75-325 mg daily	Neither or ASA or OAC
CHA ₂ DS ₂ -VASc ≥ 2 in men CHA ₂ DS ₂ -VASc ≥ 3 in women	TSOAC* > VKA	TSOAC* or VKA
Mechanical valve (modern)	VKA: INR 2.0-3.0 (AVR) VKA: INR 2.5-3.5 (MVR)	

ASA = acetylsalicylic acid; TSOAC = target-specific oral anticoagulants; VKA = vitamin K antagonists; AVR = aortic valve replacement; MVR = mitral valve replacement.

Camm A, et al. 2012 ESC Guidelines. *Eur Heart J*. 2012;33:2719-2747. January C, et al. *J Am Coll Cardiol*. 2014;64(21):e1-e76. January C, et al. AHA/ACC/HRS Guidelines. *Circulation*. 2019;74(1):104-132. ACC. 2017 AHA/ACC Focused Update. *J Am Coll Cardiol*. 2017;70:252-289.

How Lifestyle Affects AF

Smoking

Quitting *decreased AF by 36%*

Alcohol

10% **↑ risk** with 1 drink/day

Impact of comorbidities on AF

- OSA treatment can *reduce AF*
- HTN control can *reduce AF*
- DM **↑ risk** of AF
- Obesity **↑ risk** of *new onset AF* by 40%;
weight loss *reduces AF* burden and recurrences

Lifestyle choices can affect AF

- Stimulants (caffeine, adrenergic drugs)
- Mediterranean diet may *reduce AF*
- Mindset and stress (yoga *reduced AF* by 24%)
- Physical activity *reduces AF*

Subzwari S, et al. *Cureus*. 2018;10(5):e2682. Foy A, et al. *Am J Cardiol*. 2018;121:1072-1075. Pathak P, et al. *J Am Coll Cardiol*. 2015;65:2159-2169.

AF: Risk Factor Management & Lifestyle Modification

Aggressive Risk Factor Management

Weight Management and Exercise	Hyperlipidemia	Obstructive Sleep Apnea	Hypertension	Diabetes
• Education • Diet plan • Initial target: >10% wt loss • Final target: BMI <27 kg/m² • Avoid weight fluctuation • Exercise: 30 min, 3-4x/wk ↑ up to 250 min/wk	• Initial lifestyle measures • At 3 mo: – Start statins if LDL >100 mg/dl • Add fibrates if TG >230 mg/dl • Start fibrates if TG >500 mg/dl	• Overnight sleep study • CPAP if AHI ≥30; or ≥20/h with resistant HTN or daytime somnolence • Check adherence: regular CPAP machine data download	• Home BP diary: 2- 3x daily • Reduce salt • Start ACEI or ARB • BP target (mmHg) rest: <130/80 peak exercise: <200/100	• Glucose tolerance test • Lifestyle measures • At 3 mo: – Metformin if HbA1c >6.5% • Diabetes clinic or endocrine review

Smoking cessation & alcohol abstinence (or reduction to 30 g per week)

BMI = body mass index; LDL = low-density lipoprotein; TG = triglycerides; CPAP = continuous positive airway pressure; AHI = apnea-hypopnea index; HTN = hypertension; BP = blood pressure; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; HbA1c = hemoglobin A1c.

Chung M, et al. *J Am Coll Cardiol*. 2020;75(14):1689-1713.

Shared Decision-Making (SDM) in AF

While SDM in AF frequently centers around anticoagulation, it is reasonable to apply SDM to all aspects of AF management:

Remind why treatment is important

Ensure original treatment decisions are still appropriate to current patient situation and priorities

Identify adherence factors

Accessibility (cost barriers, delayed prescription fill)
Organization (fixed packaging, pill boxes)
Administration (reminders)

- Ongoing process that starts during initial treatment discussion
- Evolves over time as a series of “problem-solving” discussions that refine individualized care plans to live well with treatment
- Can uncover which aspects of an individual situation need intervention *as well as* the situation-specific action required

Brand-McCarthy S, et al. *Circ Cardiovasc Qual Outcomes*. 2020;13:e006080.

Goals of SDM

- To help patients and clinicians make shared and informed decisions that integrate:
 - Known risks and benefits of treatment
 - Pertinent patient-specific situations
 - Patient preferences

What SDM does





Enhances communication
Facilitates identification of individualized treatment options

What SDM is *not*



A checklist of tasks to be completed

Noseworthy P, et al. *J Interv Card Electrophysiol*. 2019;56:159-163.



“ATRIAL FIBRILLATION IS THE GIFT THAT KEEPS ON GIVING”

- AF is chronic so you will get to be good friends with your long-term patients
- Keep goals realistic; total prevention with AADs is unlikely in the absence of a correctable underlying disorder
- AAD therapy selection should be based on anticipated efficacy, proarrhythmic risk, organ toxicity, and effects on nodal, conductive system, and LV function
 - AF can be refractory to amiodarone, which can also have significant long-term toxicity
- No new antiarrhythmic agents near FDA approval in near future
- Catheter ablation can be effective and is growing but still has limitations
- Rate control has similar long-term efficacy on mortality
- Lifestyle modifications may be part of the treatment approach for patients with AF but will not be a panacea
- If you remember nothing else, remember this: “Protect the brain” with proper antiembolic strategies in high-risk patients with AF

Reducing the Burden of **ATRIAL FIBRILLATION:** A Whiteboard Animated Tour of Antiarrhythmic Drugs for Cardiologists



**RECEIVE YOUR
CERTIFICATE
OF CREDIT!**

Let us know how you
liked the program!

**Please follow instructions below to obtain
your certificate**

- STEP 1 \ Go to www.medlearninggroup.com/event
 STEP 2 \ Select an event
 STEP 3 \ Log in or create your free MLG account
 STEP 4 \ Complete your evaluation
 STEP 5 \ Print your certificate and download a PDF
 of the program slides



This activity is provided by Med Learning Group.
 This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
 This activity is supported by an educational grant from Sanofi US.

9

**Complimentary
poster for the
office!**

**Supplement your
Course Learning.
It's fast and easy.**



**We'll ship it
to you directly
free of charge**

Reducing the Burden
of **ATRIAL FIBRILLATION:**

A Whiteboard Animated Tour
of Antiarrhythmic Drugs
for Cardiologists



For more information and additional resources please visit
AFIB.POSTERPROGRAM.COM

Thank you!

Overview of Atrial Fibrillation and Guidelines

Resource	Address
American College of Cardiology (ACC). Impact and consequences of atrial fibrillation. Published August 16, 2018.	https://www.acc.org/latest-in-cardiology/articles/2018/08/06/12/42/cover-story-impact-and-consequences-of-atrial-fibrillation
Benjamin EJ, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. <i>Circulation</i> . 1998;98:946-952.	https://www.ahajournals.org/doi/epub/10.1161/01.CIR.98.10.946
Centers for Disease Control (CDC). What is atrial fibrillation? Reviewed September 8, 2020.	https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
Chugh SS, et al. Epidemiology and natural history of atrial fibrillation: Clinical implications. <i>J Am Coll Cardiol</i> . 2001;37:371-378.	https://www.sciencedirect.com/science/article/pii/S0735109700011074
Feinberg WM, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. <i>Arch Intern Med</i> . 1995;155:469-473.	https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/620157
Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. <i>Circulation</i> . 2006;114:700-752.	https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.106.177031
Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>J Am Coll Cardiol</i> . 2006;48:e149-e246.	http://www.lippman.org/ACC/clinicalguidelines/AFGuidelinesFullText.pdf
Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) [published online ahead of print, 2020 Aug 29]. <i>Eur Heart J</i> . 2020;ehaa612..	https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa612/5899003
January CT, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American	https://www.sciencedirect.com/science/article/pii/S0735109719302098

Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i> . 2019;74:104-132.	
January C, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i> . 2014;64:e1-e76.	https://www.sciencedirect.com/science/article/pii/S0735109714017409
Miyasaka Y, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. <i>Circulation</i> . 2006;114:119-125.	https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.105.595140
Thom T, et al. Heart disease and stroke statistics—2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> . 2006;113:e85-e151.	https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.105.171600
Wang TJ, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. <i>Circulation</i> . 2003;107:2920-2925.	https://www.ahajournals.org/doi/epub/10.1161/01.CIR.0000072767.89944.6E

Rate vs Rhythm Control

Resource	Address
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. <i>N Engl J Med</i> . 2002;347:1825-1833.	https://www.nejm.org/doi/10.1056/NEJMoa021328
AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. <i>J Am Coll Cardiol</i> . 2003;42:20-29.	https://www.sciencedirect.com/science/article/pii/S073510970300559X
January CT, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients	https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000000041

With Atrial Fibrillation. <i>Circulation</i> . 2014;130:2071-2104.	
Boriani G, et al. Safety and efficacy of dronedarone from clinical trials to real-world evidence: Implications for its use in atrial fibrillation. <i>Europace</i> . 2019;21:1764-1775.	https://academic.oup.com/europace/article/21/12/1764/5536329
Calkins H, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. <i>Circ Arrhythmia Electrophysiol</i> . 2009;2:349-361.	https://www.ahajournals.org/doi/epub/10.1161/CIRCEP.108.824789
Camm A, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Eur Heart J</i> . 2010;31;2369-2429.	https://academic.oup.com/eurheartj/article/31/19/2369/442190
Carlsson J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. <i>J Am Coll Cardiol</i> . 2003;41:1690-1696.	https://www.sciencedirect.com/science/article/pii/S0735109703003322
Connolly SJ, et al. Dronedarone in high-risk permanent atrial fibrillation. <i>N Engl J Med</i> . 2011;365:2268-2676.	https://www.nejm.org/doi/10.1056/NEJMoa1109867
Dan GA, et al. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> . 2018;20:731-732an.	https://academic.oup.com/europace/article/20/5/731/4846844
Frommeyer G, et al. Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone. <i>Int J Cardiol</i> . 2017;228:74-79.	https://www.internationaljournalofcardiology.com/article/S0167-5273(16)33470-2/fulltext

Gillinov AM, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. <i>N Engl J Med</i> . 2016;374:1911-1921.	https://www.nejm.org/doi/10.1056/NEJMoa1602002
Goehring EL, et al. Outcomes associated with dronedarone use in patients with atrial fibrillation. <i>Am J Cardiol</i> . 2020;135:77-83.	https://www.ajconline.org/article/S0002-9149(20)30883-3/fulltext
Hagens VE, et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAtE Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. <i>Heart Rhythm</i> . 2005;2:19-24.	https://www.heartrhythmjournal.com/article/S1547-5271(04)00642-3/fulltext
Hess PL, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines - Heart Failure Program). <i>Am J Cardiol</i> . 2020;125:894-900.	https://www.ajconline.org/article/S0002-9149(19)31494-8/fulltext
Hohnloser SH, et al. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. <i>Lancet</i> . 2000;356:1789-1794.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)03230-X/fulltext
Hohnloser SH, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. <i>N Engl J Med</i> . 2009;360:668-678.	https://www.nejm.org/doi/10.1056/NEJMoa0803778
Kipp R, et al. Real-world comparison of classes IC and III antiarrhythmic drugs as an initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study. <i>JACC Clin Electrophysiol</i> . 2019;5:231-241.	https://www.sciencedirect.com/science/article/pii/S2405500X18307953?via%3Dihub
Kirchoff P, et al. Early rhythm-control therapy in patients with atrial fibrillation. <i>N Engl J Med</i> . 2020;383:1305-1316.	https://www.nejm.org/doi/10.1056/NEJMoa2019422
Konieczny KM, Dorian P. Clinically important drug-drug interactions between antiarrhythmic drugs and anticoagulants. <i>J Innov Card Rhythm Manag</i> . 2019;10:3552-3559.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252850/

Le Heuzey JY, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. <i>J Cardiovasc Electrophysiol</i> . 2010;21:597-605.	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1540-8167.2010.01764.x
Lei M, et al. Modernized classification of cardiac antiarrhythmic drugs. <i>Circulation</i> . 2018;138:1879-1896.	https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.118.035455
Marrouche N, et al. Catheter ablation for atrial fibrillation with heart failure. <i>N Engl J Med</i> . 2018;378:417-427.	https://www.nejm.org/doi/10.1056/NEJMoa1707855
Naccarelli GV, et al. Amiodarone: Pharmacology and antiarrhythmic and adverse effects. <i>Pharmacotherapy</i> . 1985;5:298-313.	https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1985.tb03434.x
Naccarelli GV, et al. Antiarrhythmic drug suppression of atrial fibrillation. <i>Bus Brief: US Cardiol</i> . 2004;1:1-5.	https://www.uscjournal.com/system/files/articles/5238_0.pdf
Naccarelli G, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. <i>Clin Med Insights Cardiol</i> . 2011;5:103-119.	https://journals.sagepub.com/doi/10.4137/CMC.S6677
Noheria A, et al. Rhythm control versus rate control and clinical outcomes in patients with atrial fibrillation. <i>JACC Clin Electrophysiol</i> . 2016;2:221-229.	https://www.jacc.org/doi/full/10.1016/j.jacep.2015.11.001
Ogawa S, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. <i>Circ J</i> . 2009;73:242-248.	https://www.istage.ist.go.jp/article/circj/73/2/73_CJ-08-0608/article
Opolski G, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. <i>Chest</i> . 2004;126:476-486.	https://journal.chestnet.org/article/S0012-3692(15)31160-0/fulltext
Packer DL, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA	https://jamanetwork.com/journals/jama/fullarticle/2728676

randomized clinical trial. <i>JAMA</i> . 2019;321:1261-1274.	
Piccini JP, et al. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. <i>Am J Cardiol</i> . 2014;114:716-722.	https://www.ajconline.org/article/S0002-9149(14)01303-4/fulltext
Pokorney SD, et al. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>Am Heart J</i> . 2020;220:145-154.	https://www.sciencedirect.com/science/article/abs/pii/S0002870319302753
Reiffel JA, et al. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). <i>Am J Cardiol</i> . 2010;105:1122-1129.	https://www.ajconline.org/article/S0002-9149(09)02842-2/fulltext
Reiffel, JA. Rate versus rhythm control pharmacotherapy for atrial fibrillation: Where are we in 2008? <i>J Atr Fibrillation</i> . 2008;1:40-52.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398794/
Roy D, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). <i>Am J Cardiol</i> . 1997;80:464-468.	https://www.ajconline.org/article/S0002-9149(97)00396-2/fulltext
Roy D, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. <i>N Engl J Med</i> . 2008;358:2667-2677.	https://www.nejm.org/doi/10.1056/NEJMoa0708789
Singh BN, et al. Amiodarone versus sotalol for atrial fibrillation. <i>N Engl J Med</i> . 2005;352:1861-1872.	https://www.nejm.org/doi/10.1056/NEJMoa041705
Singh D, et al. Dronedarone for atrial fibrillation: Have we expanded the antiarrhythmic armamentarium? <i>J Am Coll Cardiol</i> . 2010;55:1569-1576.	https://www.sciencedirect.com/science/article/pii/S0735109710005061
Singh BN, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. <i>N Engl J Med</i> . 2007;357:987-999.	https://www.nejm.org/doi/10.1056/NEJMoa054686
Singh SN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: A Veterans Affairs Cooperative Studies Program Substudy. <i>J Am Coll Cardiol</i> . 2006;48:721-730.	https://www.sciencedirect.com/science/article/pii/S0735109706013222

Touboul P, et al. Dronedaron for prevention of atrial fibrillation: A dose-ranging study. <i>Eur Heart J</i> . 2003;24:1481-1487.	https://academic.oup.com/eurheartj/article/24/16/1481/548390
Van Gelder IC, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. <i>N Engl J Med</i> . 2002;347:1834-1840.	https://www.nejm.org/doi/10.1056/NEJMoa021375
Van Gelder IC, et al. Lenient versus strict rate control in patients with atrial fibrillation. <i>N Engl J Med</i> . 2010;362:1363-1373.	https://www.nejm.org/doi/10.1056/NEJMoa1001337
Vora A, et al. Control of heart rate versus rhythm in rheumatic atrial fibrillation: A randomized study. <i>J Cardiovasc Pharmacol Ther</i> . 2004;9:65-73.	https://journals.sagepub.com/doi/10.1177/107424840400900201
Waktare JEP, et al. Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm. <i>Am J Cardiol</i> . 1998;81(5 suppl 1):3C-15C.	https://www.ajconline.org/article/S0002-9149(98)00181-7/fulltext
Wiggins B, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. <i>Circulation</i> . 2016;134:e468-e495.	https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000000456
Wolbrette DL, et al. A quarter of a century later: What is dofetilide's clinical role today? <i>J Cardiovasc Pharm Ther</i> . 2019;24:3-10.	https://journals.sagepub.com/doi/epub/10.1177/1074248418784288
Wolbrette D, et al. Dronedaron for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. <i>Vasc Health Risk Manag</i> . 2010;6:517-523.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922313/
Wyse GD, Gersh BJ. Atrial fibrillation: A perspective: Thinking inside and outside the box. <i>Circulation</i> . 2004;109:3089-3095.	https://www.ahajournals.org/doi/epub/10.1161/01.CIR.0000132611.01101.DC
Wyse DG, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. <i>N Engl J Med</i> . 2002;347:1825-1833.	https://www.nejm.org/doi/10.1056/NEJMoa021328

Xiao D, Wenhui D. A meta-analysis of ibutilide versus amiodarone in cardioversion efficiency and safety of atrial fibrillation and atrial flutter. <i>Heart</i>. 2011;97(suppl 3):A122.	https://heart.bmj.com/content/97/Suppl_3/A122.1
Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. <i>Circulation</i>. 2012;125;381-389.	https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.111.019927

Shared Decision-Making and Interdisciplinary Care

Resource	Address
Brand-McCarthy SR, et al. Can shared decision making improve stroke prevention in atrial fibrillation?: Implications of the updated guidelines. <i>Circ Cardiovasc Qual Outcomes</i>. 2020;13:e006080.	https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.119.006080
Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) [published online ahead of print, 2020 Aug 29]. <i>Eur Heart J</i>. 2020;ehaa612.	https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa612/5899003
Noseworthy PA, et al. Shared decision-making in atrial fibrillation: Navigating complex issues in partnership with the patient. <i>J Interv Card Electrophysiol</i>. 2019;56:159-163.	https://link.springer.com/article/10.1007/s10840-018-0465-5